## RECEIVED CENTRAL FAX CENTER

AUG 1-1 2006

Serial No. 10/756,124
Docket No. MICRODOSE 99.02 CON2
Amendment C Under Rule 116

## **AMENDMENTS TO THE CLAIMS**

Please cancel claim 4, without prejudice. Kindly amend claims 1, 5, and 21, as shown below.

This listing of claims will replace all prior versions and listings of claims in the Application:

Claim 1 (currently amended): A pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to fluids for controlled release of said powdered pharmaceutical ingredients at a selected site or sites within a patient's alimentary canal, [.]

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes.

Claim 2 (canceled)

Claim 3 (previously presented): A pharmaceutical delivery package according to claim 1, wherein said membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 4 (canceled)

Claim 5 (currently amended): A pharmaceutical delivery package according to claim 1, and consisting of fixed unit dose quantities of two or more different powdered pharmaceutical ingredients separated from one another on an ingestible membrane which forms a single delivery package, wherein said ingestible membrane has selected permeability porosity to

HAYES SOLOWAY P.C. 3450 E. SUNRISE DRIVE, SUITE 140 TUCSON, AZ 65718 TEL. 520.882,7623 FAX. 520.882,7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

PAGE 5/11 \* RCVD AT 8/11/2006 6:31:29 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-3/16 \* DNIS:2738300 \* CSID:520 8827643 \* DURATION (mm-ss):03-08

Serial No. 10/756,124
Docket No. MICRODOSE 99.02 CON2
Amendment C Under Rule 116

fluids for controlled release of said powdered pharmaceutical ingredients at a selected site or sites within a patient's alimentary canal, further comprising an adhesive on an outer surface of the membrane.

Claim 6 (previously presented): A pharmaceutical delivery package according to claim 5, wherein the adhesive is acid or alkaline activatable.

Claim 7 (original): A pharmaceutical delivery package according to claim 5, and further comprising an alkali or acid dissolvable membrane covering the adhesive.

Claim 8 (original): A pharmaceutical delivery package according to claim 1, wherein said membrane comprises a material which expands upon contact with acid or alkaline in the alimentary canal, whereby to become more porous.

Claim 9 (previously presented): A pharmaceutical delivery package according to claim 1, wherein said membrane is formed into a tablet or capsule.

Claim 10 (previously presented): A pharmaceutical delivery package according to claim 1, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 11 (previously presented): A pharmaceutical delivery package according to claim 1, wherein said powdered pharmaceutical ingredients are segregated from one another in a tablet.

Claim 12 (previously presented): A pharmaceutical delivery package according to claim 1, wherein said powdered pharmaceutical ingredients are encapsulated within inert coatings.

HAYES SOLOWAY P.C. 3450 E. SUNRISE DRIVE, SUITE 140 TUCSON, AZ 85718 TEL. 520.882.7623 FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

PAGE 6/11 \* RCVD AT 8/11/2006 6:31:29 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-3/16 \* DNIS:2738300 \* CSID:520 8827643 \* DURATION (mm-ss):03-08

Serial No. 10/756,124
Docket No. MICRODOSE 99.02 CON2
Amendment C Under Rule 116

Claim 13 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Ketoconazole and testosterone.

Claim 14 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Valacylovir and one or both of Cimetidine and Probenecid.

Claim 15 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazine, Prazosin or Digoxin.

Claim 16 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Omeprazole and B12.

Claim 17 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Omeprazole and Clarithoromycin.

Claim 18 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Tamoxifen and a diuretic.

Claim 19 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Isotretinoin and an oral contraceptive.

Claim 20 (previously presented): A pharmaceutical delivery package according to claim 1, comprising a mixture of Metformin HCl and Sulfonylurea.

Claim 21 (currently amended): A controlled release pharmaceutical delivery package consisting of fixed unit dose quantities of two or more different powdered pharmaceutical

HAYES SOLOWAY P.C. 3450 E. SUNRISE DRIVE, SUITE 140 TUCSON, AZ 85718 TEL. 520.882.7623 FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL 603.668.1400
FAX. 603.668.8567

PAGE 7/11 \* RCVD AT 8/11/2006 6:31:29 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-3/16 \* DNIS:2738300 \* CSID:520 8827643 \* DURATION (mm-ss):03-08

Serial No. 10/756,124

Docket No. MICRODOSE 99.02 CON2

Amendment C Under Rule 116

ingredients combined in a single delivery package, wherein said delivery package comprises an ingestible membrane, and said two or more different powdered pharmaceutical ingredients comprise combinations of active pharmaceutical ingredients selected from the group consisting of (a) a mixture of Ketoconazole and testosterone, (b) a mixture of Valacylovir and one or both of Cimetidine and Probenecid, (c) a mixture of Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazinc, Prazosin or Digoxin, (d) a mixture of Omeprazole and B12, (e) a mixture of Omeprazole and Clarithoromycin, (f) a mixture of Tamoxifen and a diuretic, (g) a mixture of Isotretinoin and an oral contraceptive, and (h) a mixture of Metformin HCl and Sulfonylurea, further comprising an adhesive on an outer surface of the membrane.

HAYES SOLOWAY P.C. 3450 E. SUNRISE DRIVE, SUITE 140 TUCSON, AZ 85718 TEL. 520.882.7623 FAX. 520.882.7643

175 CANAL STREET MANCHESTER, NH 03101 TEL 603.668.1400

TEL 603.668.1400 FAX. 603.668.8567

PAGE 8/11 \* RCVD AT 8/11/2006 6:31:29 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-3/16 \* DNIS:2738300 \* CSID:520 8827643 \* DURATION (mm-ss):03-08